Key statistics
As of last trade, Cytodyn Inc (CYDY:QBB) traded at 0.157, 41.46% above the 52 week low of 0.111 set on Aug 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.162 |
---|---|
High | 0.162 |
Low | 0.1522 |
Bid | -- |
Offer | -- |
Previous close | 0.1599 |
Average volume | 908.14k |
---|---|
Shares outstanding | 1.21bn |
Free float | 1.21bn |
P/E (TTM) | -- |
Market cap | 194.26m USD |
EPS (TTM) | -0.0527 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 17:03 BST.
More ▼
- September 2024 Letter to Shareholders
- CytoDyn Engages Leading CRO For Phase II Inflammation Trial
- CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
- CytoDyn Announces Settlement with Amarex Clinical Research LLC
- CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
- CytoDyn to Host Webcast to Provide Company Update
- May 2024 Letter to Shareholders
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
More ▼